Effect of Dahuang Zhechong Pills combined with TACE on VEGF, MMP-2, TGF-β1 and immune function of patients with primary liver cancer (blood stasis and collaterals blocking type).
10.19540/j.cnki.cjcmm.20200716.501
- Author:
Chao-Ming DAI
1
;
Song JIN
1
;
Ji-Zhou ZHANG
1
Author Information
1. Wenzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University Wenzhou 325000, China.
- Publication Type:Journal Article
- Keywords:
Dahuang Zhechong Pills;
MMP-9;
TGF-β1;
VEGF;
blood stasis and collaterals blocking type;
hepatic artery chemoembolization;
immune function;
primary liver cancer
- MeSH:
Carcinoma, Hepatocellular;
Chemoembolization, Therapeutic;
Drugs, Chinese Herbal;
Humans;
Liver Neoplasms/drug therapy*;
Matrix Metalloproteinase 2;
Transforming Growth Factor beta1;
Vascular Endothelial Growth Factor A;
Vascular Endothelial Growth Factors
- From:
China Journal of Chinese Materia Medica
2021;46(3):722-729
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the effects of Dahuang Zhechong Pills combined with hepatic arterial chemoembolization(TACE) on tumor index and immune function of patients with primary liver cancer(blood stasis and collaterals blocking type), observe its application values in treatment of such patients, and provide effective treatment means for this disease. From June 2019 to December 2019, 79 patients with confirmed primary liver cancer(blood stasis and collaterals blocking type) treated in Wenzhou Hospital of Traditional Chinese Medicine were included in this study, all of which were grouped with random number table method before inclusion in this study. 40 patients in the control group were treated with TACE, while 39 patients in the observation group were treated with Dahuang Zhechong Pills combined with TACE. The efficacy was compared between two groups after 4 weeks of treatment. The immune function indexes of serum CD4~+ cells, CD4~+/CD8~+, CD3~+ cells of the observation group were higher than those in control group after treatment(P<0.05), and tumor indexes such as serum alpha-fetoprotein(AFP), carbohydrate antigen 199(CA199) and glutamic-pyruvic transaminase(ALT), total bilirubin(TBiL) levels were lower than those in the control group, with statistically significant differences(P<0.05). Plasma vascular endothelial growth factor(VEGF), transforming growth factor-β1(TGF-β1), and matrix metalloprotei-nase-2(MMP-2) levels in the observation group were lower than those in the control group after treatment, with statistically significant differences(P<0.05). The total effective rate of the observation group was 87.18%, higher than 67.50% in the control group, and the benefit rate was 94.87% in the observation group, higher than 85.00% in the control group(P<0.05). The total incidence of adverse reactions such as bone marrow suppression, gastrointestinal reaction, fever, renal function injury and peripheral nerve injury in the observation group was 48.72%, lower than 82.50% in the control group, with statistically significant difference(P<0.05). In summary, the combination of Dahuang Zhechong Pills with TACE could improve immunity, protect liver function, and reduce the risk of metastasis and the incidence of adverse reactions from chemotherapy, so it is worth popularizing for patients with primary liver cancer(blood stasis and collaterals blocking type).
